Eli Lilly Goes All-In: $1B Investment for India Pharma Hub

Eli Lilly has announced plans to invest over USD 1 billion in India to expand its manufacturing and supply capabilities through strategic partnerships with local pharmaceutical companies.

The investment will support the production of key therapies across areas such as obesity, diabetes, Alzheimer’s disease, cancer, and autoimmune disorders. While Lilly does not currently operate its own manufacturing facility in India, it is actively engaging with contract manufacturers and is in the process of establishing a new manufacturing and quality centre in Hyderabad.

This initiative is part of Lilly’s broader global expansion strategy, which includes a USD 5 billion investment in its U.S. operations. In India, the recent launch of Mounjaro, Lilly’s breakthrough weight-loss drug, has significantly increased awareness of obesity treatments—particularly relevant as India is projected to have the second-largest obese population globally by 2050.

The investment underscores Lilly’s long-term commitment to India as a key hub for both supply chain resilience and market growth.

News by Rahul Yelligetti.